ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,320.76
0.43%
Dow Jones
42,343.72
0.40%
Gold vs US Dollar
2,650.70
-0.82%
Brent Oil
71.965
1.43%
Bitcoin
65,735.79
0.85%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE
  6. Eli Lilly and Co (LLY)

  7. Eli Lilly and Co (LLY) News

Eli Lilly (LLY)

Eli Lilly and Co
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:LLY
DateTimeSourceHeadlineSymbolCompany
25/09/202411:45PR Newswire (US)New data show Lilly's EBGLYSS™ (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitisNYSE:LLYEli Lilly and Co
24/09/202411:00PR Newswire (US)Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's DiseaseNYSE:LLYEli Lilly and Co
18/09/202421:19Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
17/09/202422:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
17/09/202422:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
17/09/202422:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
17/09/202422:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
17/09/202422:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
13/09/202421:07PR Newswire (US)FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic DermatitisNYSE:LLYEli Lilly and Co
12/09/202421:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
12/09/202410:30PR Newswire (US)Lilly expands manufacturing footprint in Ireland with $1.8 billion investmentNYSE:LLYEli Lilly and Co
10/09/202416:57PR Newswire (US)With once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetesNYSE:LLYEli Lilly and Co
10/09/202416:18PR Newswire (US)Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetesNYSE:LLYEli Lilly and Co
10/09/202411:02IH Market NewsApple Loses EU Dispute; Google’s $2.7 Billion Fine Upheld; Oracle Shares Surge 9%NYSE:LLYEli Lilly and Co
09/09/202412:03Edgar (US Regulatory)Form 8-K - Current reportNYSE:LLYEli Lilly and Co
09/09/202411:45PR Newswire (US)Lilly appoints Lucas Montarce as executive vice president and chief financial officerNYSE:LLYEli Lilly and Co
05/09/202411:45PR Newswire (US)In a first-of-its-kind fixed dose study, once weekly insulin efsitora alfa leads to A1C reduction similar to daily insulinNYSE:LLYEli Lilly and Co
04/09/202421:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
04/09/202411:00PR Newswire (US)Lilly and EVA Pharma collaborate to expand access to baricitinib in low- to middle-income countriesNYSE:LLYEli Lilly and Co
28/08/202421:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
28/08/202410:50IH Market NewsHigh Volatility Expected in Nvidia Report, Ambarella Soars 20%, Hertz Strengthens Board, Apple Cuts JobsNYSE:LLYEli Lilly and Co
27/08/202411:45PR Newswire (US)Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesityNYSE:LLYEli Lilly and Co
26/08/202421:47Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:LLYEli Lilly and Co
26/08/202421:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
26/08/202413:58IH Market NewsIBM Closes China Research Division, Uber Fined $324M, Starliner to Return Without AstronautsNYSE:LLYEli Lilly and Co
23/08/202421:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
22/08/202417:54Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:LLYEli Lilly and Co
22/08/202415:00PR Newswire (US)Lilly to participate in Morgan Stanley 22nd Annual Global Healthcare ConferenceNYSE:LLYEli Lilly and Co
21/08/202421:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
21/08/202413:12IH Market NewsWalmart Sells JD.com Stake, Microchip Suffers Cyberattack, Union Pacific Warns of Strike in Canada, and Latest NewsNYSE:LLYEli Lilly and Co
 Showing the most relevant articles for your search:NYSE:LLY

Your Recent History

ASX
RDT
Red Dirt Metals
UNSW3
C20ETH
CRYPTO20
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved